Method for treating malignant spinal cord tumor cases with chemotherapy

FIELD: medicine.

SUBSTANCE: method involves making lumbar puncture in postoperative period. Subarachnoid space is catheterized and 5 ml of liquor is taken and incubated with 5 mg of Nimustin for 30 min at 38°C and introduced through the catheter into the subarachnoid space.

EFFECT: enhanced effectiveness of treatment; reduced toxic effect.

 

The invention relates to medicine, namely to Oncology, and can be used in adjuvant chemotherapy of tumours of the Central nervous system.

There is a method of treatment of tumors of the Central nervous system (Agiesta, Bielenski. "Brain tumors of astrocytic number", Leningrad, "Medicine", 1985, str): the introduction of drugs intravenously according to the standard technique, as well as intra-arterial (intracarotid) introduction of cyclophosphamide (2000 mg for 62 minutes), ACNU (nimustine) (2 mg/kg) and topical application of cyclophosphamide in the tumor bed dose of 200-400 mg of the disadvantages of the method of treatment of tumors of the Central nervous system is the high toxicity of chemotherapy are: headaches, nausea, vomiting, flushing, etc.

Known "Method endolyumbalno drug administration in intracerebral malignant tumors (see Zemstvo A.G. "Multiform glioblastoma brain", Leningrad, "Medicine", 1976, str), chosen as a prototype.

The method includes endolyumbalno introduction chemotherapy: methotrexate 0.25 mg/kg of body weight of the patient, the course of 120-180 mg; beginning with 7-10 days after the operation, i.e. by repeated punctures (5-7 injections every other day).

The disadvantage of this method is low efficiency and high toxicity endolyumbalno of methotrexate with intracerebral zlocesto the different tumors.

The aim of the invention is to increase the efficiency and reduce the toxicity of treatment of malignant tumors of the spinal cord.

This objective is achieved in that in the postoperative period the patient perform a lumbar puncture, kateteriziruyut subarachnoid space, take 5 ml of the liquor, incubated CSF with chemotherapy (ACNU, nimustine) in an amount of 5 mg in vitro at a temperature of 38°C for 30 minutes and injected through the catheter into the subarachnoid space, the procedure is carried out 2 times with an interval of 7 days.

The invention "Method of chemotherapy of malignant tumors of the spinal cord is new, as is unknown level of medicine in the field of cancer chemotherapy CNS by endolyumbalno introduction.

The novelty of the invention lies in the fact that for the treatment of malignant tumors of the spinal cord using the introduction of ACNU (nimustine) Autostore through endolyumbalno catheter.

The invention is industrially applicable as it can be used in health care, in medical institutions for the treatment of patients with tumors of the Central nervous system, cancer research institutes, breast care clinics and other clinical settings.

"The way the chemotherapy of malignant tumors of the spinal cord" is performed as education is om.

In the postoperative period the patient perform a lumbar puncture needle (Tuohy, kateteriziruyut the subarachnoid space. Take the cerebrospinal fluid of a patient in an amount of 5 ml and incubated with the chemical (ACNU 5 mg) in vitro at a temperature of 38°C for 30 minutes, and then endolyumbalno administered to the patient. The procedure is carried out twice with an interval of 7 days. Course autolymphochemotherapy ACNU repeated after 6-8 weeks.

An example of a specific implementation of the Method of chemotherapy of malignant tumors of the spinal cord"

Sick Babies N.A., 35 years, history 7944/0. He enrolled in the Department. INC RNII 26.03.03 was diagnosed with Anaplastic ependymoma cauda equina. After hemilaminectomy LII-LIVpartial removal of the tumor (23.04.02, RSMU, g/a No. 815-3154). Condition after a course of DHT SOD 40 Gy (05.-06.2002 RNII).

On CT of the lumbar-sacral spine from 14.03.2003,: defect of the right palubicki LIIIvertebrae from spinal canal adjacent volumetric education in sizes 4×1,5×1.7 cm in length up to LIVvertebra. Conclusion: CT signs preceding growth of education.

With 26.03.2003, 06.10.2003, Department INC RNII held 4 year autolymphochemotherapy with ACNU in a total dose of 40 mg, for autolymphochemotherapy side effects and manifestations toxi the particular chemotherapy drugs (headaches, nausea, vomiting) is not marked.

On CT of the lumbar-sacral spine from 30.03.2004, data for a tumor of the cauda equina not.

Technical and economic efficiency "Way of chemotherapy for patients with malignant tumors of the spinal cord" is that the use of ACNU when endolyumbalno chemotherapy on Autostore allows you to reduce the size of the tumor of the spinal cord up to complete disappearance, reduce the toxicity of cytostatic agents, the incidence of side effects and thus increase the effectiveness of chemotherapy.

The way the chemotherapy of malignant tumors of the spinal cord, including endolyumbalno introduction of chemotherapy, characterized in that in the postoperative period the patient perform a lumbar puncture, kateteriziruyut subarachnoid space, take 5 ml of CSF and incubated with 5 mg of nimustine at a temperature of 38°C for 30 min and injected through the catheter into the subarachnoid space, the procedure is carried out 2 times with an interval of 7 days.



 

Same patents:

FIELD: organic chemistry, chemistry of peptides.

SUBSTANCE: invention proposes derivative of kahalalide F that is not a mixture of isomers known as kahalalide F wherein a derivative has structure comprising a cyclic moiety and by-side chain and prepared from the formula (I): . This derivative differs from the formula (I) by one or more of the following features: 1-2 amino acids that are not identical with that's as amino acids in the structural formula (I); absence of one or two amino acids in by-side chain of the structural formula (I); 1-10 additional methylene groups in acyl group of the by-side chain of the structural formula (I); 1-5 methylene groups that are absent in acyl group of the by-side chain of the structural formula (I); 1-3 substitutes added to acyl group of the by-side chain of the structural formula (I); 5-methyl-substitute that is absent in acyl group of the by-side chain, and absence of acyl group of the by-side chain.

EFFECT: new structure of compound.

12 cl, 5 tbl, 60 ex

FIELD: medicine, oncology, pharmacy.

SUBSTANCE: invention describes a liquid pharmaceutical composition used in treatment of cancer and comprising vinorelbin as an active component and is useful for incapsulation into soft capsules. The liquid oral pharmaceutical composition useful as a liquid filling agent composition for the dosed formulation as a soft capsule comprises vinorelbin or its pharmaceutically acceptable salt, in particular, vinorelbin tartrate, ethanol, water, glycerol and polyethylene glycol. Also, invention relates to a method for preparing cancer that involves oral administration to a patient a soft capsule comprising the pharmaceutical composition. The liquid composition containing vinorelbin proves the improved solubility and bioavailability for oral administration.

EFFECT: improved and valuable pharmaceutical and medicinal properties of pharmaceutical composition.

13 cl, 7 tbl, 6 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of piperidine of the general formula (I): wherein R represents (C1-C16)-alkyl or (C1-C10)-alkylphenyl wherein phenyl is optionally substituted with -OR1 wherein R1 represents (C1-C6)-alkyl, or their pharmaceutically acceptable salts. These compounds possess inhibitory activity with respect to enzyme glucosylceramide synthase and can be used in medicine in treatment of diseases caused by accumulation of glycolipid.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of derivatives.

15 cl, 2 dwg, 2 tbl, 15 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with applying a vasculodestroying agent or its pharmaceutically acceptable salt to be introduced for a warm-blooded animal as divided dosages to obtain anti-tumor effect. In particular, a vasculodestroying agent is being ZD6126, AC-7700, combrestatin A4 phosphate or their pharmaceutically acceptable salts. Moreover, total daily dosage of vasculodestroying agent is divided into two or more equal or unequal parts, and interval of time between introduction of every part corresponds to above 0 to about 6 h. The innovation enables to obtain greater anti-tumor effect against the one obtained at introducing the same total dosage of vasculodestroying agent as a single dosage.

EFFECT: higher efficiency of therapy.

18 cl, 2 dwg

FIELD: immunology, in particular method for influence on immune system.

SUBSTANCE: in claimed method pathological biologically active elements (PBA-elements) are obtained from organism or foreign source. Then PBA-elements are converted to liquid slurry or biological organism fluid is enriched with PBA-elements. Obtained slurry or PBA-element enriched fluid is exposed with optical light optionally in presence of one or more photochemical agents. Exposed liquid slurry of PBA-elements or exposed PBA-element enriched biological fluid is administrated in body lymphatic system. Method of present invention is useful in treatment of immunotherapy of human and animals, including therapy of cancer, autoimmune and viral diseases.

EFFECT: new method for inducing of general immune response.

16 cl, 2 ex

FIELD: molecular pharmacology, in particular human endostatin preparation and method for production thereof.

SUBSTANCE: claimed preparation is isolated after cell incubation E.coli BL21 (DE3) in cultural medium up to dense level of 0.4-0.6 OD6-00. Cell contains plasmide vector pBSH-ED15 or pBSH-ED16 having size of 6675 n.p. and gene of canamicine resistance gene; vector contains replicative sites pUS ori and M13 and gene encoding lac-repressor controlled by T7-promoter, and finished product has purity of 99 % and apyretic properties. Claimed preparation is obtained by expression of endostatin gene using plasmide DNA containing in E.coli cells; product refolding and purification, wherein expression is carried out in E.coli BL21 (DE3) cells, transformed by recombinant plasmide DNA pBSH-ED15 or pBSH-ED16. Cells are cultivated in cultural medium up to dense level of 0.4-0.6 OD6-00, then 0.1-0.3 mM of isopropyltiogalactoside is added into medium and cultivation is carried out for 2-3 h up to product accumulation. Further cells is exposed with ultrasound for 50-70 s at 0°C in presence of 0.1 % sodium deoxycholate. Bodies are dissolved in presence of 1 % sodium N-lauryl sarcosine. Suspension is multiply washed and centrifuged at 5000 g. In refolding process oxidation with air oxygen is carried out for 35 h, and target product is purified using chromatography depending on used incorporated plasmide.

EFFECT: apyretic product of high purity.

6 cl, 9 ex, 7 dwg

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to the injectable galenic composition used in diagnosis or photodynamic therapy and to a method for its preparing. The composition comprises the following components: compound of the general formula (I) given in the invention description wherein R2 means hydrogen atom, hydroxyl group (-OH) or group -COOR4 wherein R4 means hydrogen atom or (C1-C12)-alkyl, or (C3-C12)-cycloalkyl; R3 means hydrogen atom, -OH or (C1-C12)-alkyl, or (C1-C12)-alkoxyl, and symbol * means asymmetric carbon atom in form of alkaline metal salt in the amount not exceeding 1 weight% to the total weight of the composition (10 mg/ml) as a photosensitizing agent and a filling agent in an aqueous phase comprising at least a mixture of benzyl alcohol and ethanol or propylene glycol as a solubilizing agent for a photosensitizing agent and a surface-active substance in the amount not exceeding 20 wt.-% to the total mass of the composition under condition that when Cremophore represents a surface-active substance then its amount must not exceed 5 weigh% to the total weight of the composition.

EFFECT: improved preparing method, valuable properties of composition.

18 cl, 7 tbl

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of mycanolide of the formula (I): corresponding to the general subformulae (I)1 and (I)2 wherein L, R1 and R2 have values given in the invention description. Also, invention relates to a medicinal agent and pharmaceutical composition based on compounds of the formula (I), and to using compounds of the formula (I) for preparing a medicinal agent designated for inhibition of activity of DNA polymerases and treatment of diseases arising as result of anomalous cellular proliferation. Invention provides preparing new derivatives of mycanolide possessing the valuable pharmaceutical effect.

EFFECT: valuable medicinal and biochemical properties of derivatives.

12 cl, 2 tbl, 52 ex

FIELD: medicine.

SUBSTANCE: preparation belongs to decapeptides considered to be an analog of receptor-binding fragment of TGFα from 22 to 31 amino acids in which the eighth amino acid residue Lys is substituted with Ser residue. The analog is bindable to wide range of cytotoxic agents and operate as vector in directed delivery of antitumor agents to tumor cells. The preparation also comprises decapeptide conjugate with a cytotoxic agent showing selective action with respect to tumors and capable of reducing tumor cells resistivity to cytotoxic agents. Conjugated parts are bound by a bond scissile with respect to acid hydrolysis. Another embodiment of the invention is related to pharmaceutical composition containing effective quantity of conjugate and carrier applicable as intravenous injections.

EFFECT: enhanced effectiveness of treatment; high antitumor action selectivity.

6 cl, 2 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: the present innovation depicts the series of chimeric analogs of somatostatin-dopamine that keep activity of somatostatin and dopamine in vivo, for example: 6-n-propyl-8β-ergolinylmethylthioacetyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2.

EFFECT: higher efficiency.

17 cl, 22 ex

FIELD: molecular toxicology and extracorporal therapy.

SUBSTANCE: invention relates to extracorporal device containing solution wherein said solution comprises reagent representing biothines three-operably bonded via linkers having toxin-bonding region. Biothine-bonding sites are attaches to effecter molecules for goal-oriented toxin removing from blood circulation system.

EFFECT: method for blood detoxication of high selectivity.

20 cl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves applying plasma exchange course with cryosorption treatment of 2.5-3 volumes of circulating blood plasma within a course.

EFFECT: enhanced effectiveness in removing cytotoxic CD8+ lymphocytes, tumor necrosis factor α and interleukine-4; selective immunocorrection.

3 tbl

FIELD: medical engineering.

SUBSTANCE: device has device has plastic cylindrical body, conic covers, connecting pipes for introducing and discharging blood mounted on corks conjugated with the covers and having holes arranged coaxially with the connecting pipes, removable hoods of the connecting pipes, filters available in the device body under the conic covers and having holes in the center. One of the holes has locking member. Rings manufactured from current-conducting material are placed between the adjacent device body end faces and conic covers. The connecting pipes are made conic. Plugs with corks are screwed over the column covers. Washers are available between nuts and plugs. Body diameter-to-column length ratio is equal to 1/2-1/3.

EFFECT: improved safety, reliability and impermeability properties of column.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves taking patient blood and dividing it into plasma and erythrocyte mass by means of plasmapheresis. Autoplasma reinfusion is carried out during operation and erythrocyte mass is returned in postoperative period at the next day or one day later.

EFFECT: reduced risk of hemostasis and microcirculation disorders; stimulated fibroblast growth.

1 tbl

FIELD: medicine.

SUBSTANCE: method involves incubating antibiotics and/or chemopreparations in therapeutic doses with autoplasma 30 min at 37°C and introducing the preparations into paravaginal cellular tissue to patients suffering from genitalia diseases and into paravesical cellular tissue to patients suffering from urinary bladder diseases and into pararectal cellular tissue to patients suffering from rectum diseases. Tumor proliferation into neighboring small pelvis organs (into paravaginal and/or pararectal and/or paravesical cellular tissue) taking place, the treatment is applied twice a week.

EFFECT: increased pathological focus regression percent; reduced manifestations of drug therapy complications.

FIELD: medicine, oncology, pharmacy.

SUBSTANCE: after proving the pleural fluid sterility method involves its exfusion from pleural cavity and administration of antitumor chemopreparations. Firstly, 20 mg of bleomycetin is incubated with 20 ml of autopleural fluid, pleural fluid remained after exfusion is placed into packages "Gemakon" and centrifuged at 2000 rev/min for 60 min and liquid part is frozen. Pleural fluid is removed again as its accumulation and administration of incubated mixture of pleural fluid with bleomycetin is repeated also wherein the bleomycetin dose is increased up to 25 mg. In 2-3 days after removal of pleural liquid chemopreparations incubated with preliminary defrosted liquid part of pleural fluid are administrated each 5-7 days in the following sequence and doses: the first administration - 100 mg of cisplatin; the second administration - 100 mg of cisplatin; third, fourth and fifth administrations - 30 mg of doxorubicin and 1000 mg of cyclophosphan up to the total amount - cisplatin, 200 mg; doxorubicin, 90 mg, and cyclophosphan, 3000 mg. Method provides elimination of pleural fluid in full volume, to compensate loss of liquid, protein and trace elements, to reduce tumor size and to avoid toxic symptoms of chemotherapy. Invention can be used in the presence of exudative pleuritis in patients with lung cancer who can't to be subjected for operative and radiation treatment.

EFFECT: improved treatment method.

2 ex

FIELD: medicine, oncology.

SUBSTANCE: one should intravenously irradiate blood with low-energy He-Ne laser including recanalization and venous catheterization at installing a quartz light guide into venous lumen through the catheter. At initial stage of surgical therapy on should introduce a light guide into the lumen of V.portae to irradiate blood in the basin of portal circulation during the main stages of operation conducted. Before operation, one should intramuscularly inject halavit at the dosage of 100 mg. The innovation enables to increase efficiency of laser therapy due to affecting "a target organ" directly, that is a liver, with photomodified blood with the purpose to achieve antimutagenic and antimetastatic effect, normalize the processes of antioxidant protection, stimulate the mechanisms of anti-cancer immunity and improve local microcirculation.

EFFECT: higher efficiency of prophylaxis.

1 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with complex treatment of cancer, prevention of relapses and cancer metastases, in particular, locally metastasing cancer of large intestine and mammary gland. The innovation deals with surgical therapy and chemotherapy. Moreover, in preoperational period one should sample 200 ml patient's blood, due to centrifuging one should isolate autoleukothrombomass at the quantity of 20 ml to be placed into the first vial with chemopreparations. The rest blood elements should be put into the second vial together with plasma and chemopreparations. Separately, one should incubate the vials for 40 min at 37° C, then comes an operation in the course of which one should intravenously by drops introduce incubated blood with chemopreparations from the second vial. On removing the tumor, one should infiltrate the channel of mammary cancer or the fiber of retroperitoneal space at the side of colonic tumor localization with incubated autoleukothrombomass with chemopreparations from the first vial. The innovation enables to decrease the risk of developing local relapses, remote tumor metastases and postoperational complications.

EFFECT: decreased toxicity of therapy.

3 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: one should daily introduce medicinal mixture consisting of lidocaine, retiling, dalargin, mildronate and lidase into orbital lymphatic area, about 8-10 procedures/course followed by discrete plasmapheresis by activating cell mass due to incubation with mexidole and irradiating with ultraviolet in the course of re-infusion. The innovation provides improved visual functions due to correcting biochemical and microcirculatory disorders.

EFFECT: higher efficiency of therapy.

1 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves introducing antitumor chemo preparations with blood components. To do it, 300 ml of patient autoblood is subjected to centrifuging during 20 min at 2200 rpm. The produced 150-200 ml of autoplasma and 100 ml of packed red blood cells are placed into separate reservoirs. Cys-platinum as single dose of 100 mg is incubated with the autoplasma and cyclophosphane as single dose of 1 g is incubated with the packed red blood cells. Single doxorubicin dose of 30-50 mg is concurrently introduced with one of the preparations. When combined with cis-platinum, doxorubicin is incubated with the packed red blood cells. When combined with cyclophosphane, doxorubicin is incubated with the autoplasma. Reinfusion is carried out to bring total dose of the preparations to 150 mg of doxorubicin, 3-5 g of cyclophosphane and 200 mg of cis-platinum. Pause between the procedures is 3-4 days long.

EFFECT: avoided risk of adverse side effects; increased preparation activity; accelerated treatment course.

Up!